View of Comparison of the Efficacy of Generation 1 and 2 Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Patients with EGFR Positive Mutations

Return to Issue Details Comparison of the Efficacy of Generation 1 and 2 Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Patients with EGFR Positive Mutations Download Download PDF